In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to determine the optimal adjuvant therapy. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, discusses prognostic and predictive biomarkers that are enabling more individualised therapies to be applied in molecularly defined breast cancer subgroups.
This content is supported by Genomic Health, Inc.
